Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Tetsu Kobayashi
BACKGROUND: Immune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence prognosis in non-small cell lung cancer patients, few studies have investigated the prognostic value of immune-related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune-related adverse events after first-line treatment with immune checkpoint inhibitor-based chemotherapy for extensive-stage small cell lung cancer...
April 2024: Cancer Medicine